Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Chiasma, Inc.    CHMA

CHIASMA, INC.

(CHMA)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/27 12:04:29 pm
4.26 USD   0.00%
01/19CHIASMA : Overview
PU
01/19Chiasma Hires John Doyle as CFO
MT
01/19CHIASMA, INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chiasma to Participate in Two Investor Conferences in December

11/23/2020 | 08:02am EST

NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be presenting and participating in investor meetings at both the Piper Sandler Healthcare Conference as well as the Evercore ISI HealthCONx Conference. Details for each conference are as follows:

Piper Sandler Healthcare Conference:
Date:Monday, November 23, 2020 *
Time:10:00am ET
Format:
Fireside Chat

* All presentations for the Piper Sandler Healthcare Conference will be available on Piper Sandler’s conference portal at 10:00 am on Monday, November 23. Actual dates for the conference are November 30 – December 3.

Evercore ISI HealthCONx Conference:
Date:Thursday, December 3, 2020
Time:1:00pm ET
Format:Panel Discussion, “Easy Pills to Swallow: Oral Drugs for Large Endo Markets” - Chiasma, Crinetics and Lumos

A live audio webcast of each of the two events may be accessed under “Events & Presentations” on the News and Investors section of Chiasma’s website at https://ir.chiasma.com/events-presentations. A replay will be available for 90 days.

About Chiasma
Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale in the United States. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.

Investor Relations and Corporate Communications:
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com

Media Relations:
Patrick Bursey
LifeSci Communications
646-876-4932
pbursey@lifescicomms.com


Primary Logo


© GlobeNewswire 2020
All news about CHIASMA, INC.
01/19CHIASMA : Overview
PU
01/19Chiasma Hires John Doyle as CFO
MT
01/19CHIASMA, INC : Change in Directors or Principal Officers, Financial Statements a..
AQ
01/19Chiasma Announces Hiring of John Doyle as Chief Financial Officer
GL
01/06CHIASMA : Overview
PU
01/06CHIASMA, INC : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
01/06Chiasma Provides Corporate Update and Previews Expected 2021 Milestones
GL
2020INSIDER TRENDS : 90-Day Buying Trend Extended with Insider Purchase of Chiasma S..
MT
2020INSIDER TRENDS : Chiasma Sees 90 Days of Insider Selling, Trend Scaled Back with..
MT
2020Chiasma to Participate in Two Investor Conferences in December
GL
More news
Financials (USD)
Sales 2020 1,24 M - -
Net income 2020 -76,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -2,87x
Yield 2020 -
Capitalization 246 M 246 M -
Capi. / Sales 2020 199x
Capi. / Sales 2021 9,14x
Nbr of Employees 85
Free-Float 99,3%
Chart CHIASMA, INC.
Duration : Period :
Chiasma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHIASMA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 13,20 $
Last Close Price 4,26 $
Spread / Highest target 323%
Spread / Average Target 210%
Spread / Lowest Target 135%
EPS Revisions
Managers and Directors
NameTitle
Raj Kannan President, Chief Executive Officer & Director
David M. Stack Chairman
John Doyle Chief Financial Officer, Treasurer & Senior VP
William Ludlam Senior VP-Clinical Development & Medical Affairs
David Plante Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
CHIASMA, INC.-2.07%246
CSL LIMITED-2.70%97 068
SAMSUNG BIOLOGICS CO.,LTD.-4.36%48 099
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.12.91%42 384
BIOGEN INC.10.95%41 805
ALEXION PHARMACEUTICALS, INC.3.25%35 398